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Abstract:  
Research to-date suggests a large proportion of people living with MS are using cannabis as 
a way to self-manage symptoms, and, if not, believe that there are potential benefits in using 
this drug. Community nurses are frontline caregivers; therefore, it is likely they will come into 
contact with people who use cannabis for MS within the home setting. The literature base 
surrounding this topic is largely driven by quantitative research examining the effectiveness of 
cannabis as a medicine. This review has found that qualitative research exploring the 
experiences of people who use cannabis for MS is lacking around the world and is completely 
absent within UK nursing literature. Persons using cannabis for MS, in some cases, do not 
feel safe in discussing this with healthcare professionals through fear of being judged. This 
literature review discusses how people perceive the effectiveness of cannabis in helping 
symptoms associated with MS while also drawing upon stigma and legal concerns people 
face. Community nurses will gain more understanding of social/ political issues and how this 
influences the decision to use cannabis. The findings from this review will help community 
nurses inform their practice and enhance person-centred relationships between nurses and 
persons living with MS. 
 
Keywords: cannabis; community nursing; multiple sclerosis; person-centred; symptoms; 
stigma 
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Introduction: 
Around 100,000 people in the United Kingdom (UK) live with Multiple Sclerosis (MS) (MS 
Society, 2017). MS is a neurodegenerative condition whereby the immune system attacks and 
breaks down the protective myelin sheath surrounding the nerve fibre (Goldernberg, 2012). 
This can result in varying degrees of disability. Nerve signals can become distorted or 
neurotransmission does not occur at all. With increased survivorship for long-term conditions, 
people can live with symptoms for many years, and, in some cases, this will result in a 
decreased quality of life (Kesselring, 2005; George & Martin, 2016).  
Conventional treatments for MS usually include steroids and disease modifying therapies, 
(Chong et al, 2006; Minagar, 2013) to decrease the number and/or severity of relapses (Fox 
& Rhoades, 2012). The use of complementary and alternative therapies for MS is on the rise 
within the UK and other countries around the globe (Skovgaard et al, 2012). In a survey 
conducted by the MS Society, it was reported that one in five people who have MS use 
cannabis as a complementary therapy and as a means of self-management (MS Society, 
2017). However, Sativex, a cannabis-based medication for the management of symptoms 
related to MS was discontinued in 2014. NICE recommended that doctors should not offer this 
medication because it is deemed not cost effective. However, research does show it is 
effective in treating symptoms such as spasticity (Serpell et al, 2013) and neuropathic pain 
(Russo et al, 2016). 
Community nurses are caregivers with a commitment to promote wellbeing amongst 
vulnerable persons and to support and empower people including those in lay caregiving roles 
to participate in decision-making around their care (QNIS, 2015; NMC, 2001). However, for 
nurses working with people with MS in the community, who use cannabis for symptom control, 
there is little evidence to support and inform practice. This article was stimulated by personal 
reflections from the first author while meeting people who use cannabis for MS symptom relief, 
during a visit to a centre which supports people living with this condition. Moreover, learning 
derived from an undergraduate honours dissertation project sparked further interest in this 
topic. 
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What follows is a critical review of the literature of some issues relevant to the practice of 
community nurses working with people who have MS and are using cannabis; with the 
potential to influence more person-centred working. Person centred-practice is central to 
nursing and is underpinned by shared-decision making, being sympathetically present and 
acknowledgement of personal values regarding person-centred care (McCormack & 
McCance, 2017). Care that is safe, effective and person-centred is central to UK government 
policy and strategy such as the Care Quality strategy (2016) (Scottish Government, 2016). 
Person-centredness is both a way of working and being in which nurses help people to 
maintain or enhance their identity and wellbeing (McCormack & McCance, 2017). Person-
centred practice requires the space for risk taking and innovation (McCormack and McCance 
2017) and this is more challenging where there is an unclear evidence base to inform 
decisions. 
 
Cannabis 
Cannabis (Cannabis Sativa) is a flowering plant which contains around 400 chemicals, over 
70 of which are cannabinoids (Atakan, 2012). Two of these cannabinoids have been of interest 
within the field of medicine- THC (Tetrahydrocannabinol) and CBD (Cannabinol). THC is the 
psychoactive substance, which produces the feeling of a ‘high’ while CBD contains no 
psychoactive properties. Cannabis can be consumed in four main ways; smoking, eating, 
vaping, using oils distilled from the plant’s compounds and topical creams and lotions (Barrus 
et al, 2016). Persons using cannabis for symptom control may choose one or more of these 
methods of ingestion; and the potency of THC and/or CBD will vary, depending on product 
and person (i.e. their personal preference for product, ingestion and tolerance). Confusion can 
arise when discussing cannabis for medical use. ‘Cannabis for medical use’ could mean both 
legal cannabis-based products and illicit cannabis used for the management of symptoms 
related to a particular condition/illness. The use of medicinal cannabis has been at the centre 
of public and political debate over recent years, gaining the attention and interest of many 
researchers, but not without raising controversy, mainly around whether legalisation for 
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medical use should be permitted (Bonn-Miller et al, 2014; Troutt and DiDonato, 2015; Sexton 
et al, 2016). There has been an abundance of published literature exploring the effectiveness 
of cannabis as a medicine in helping to alleviate some symptoms associated with MS. 
However, from a scoping search, conducted by the first author, it appeared that most research 
undertaken within the UK is quantitative in nature, thus relating to the application of certain 
methodologies, methods and processes in the conduct of the research (Zajicek et al, 2005; 
Sexton et al, 2016; Kindred et al, 2017). Undoubtedly, this is useful for providing numeric and 
evaluative data relating to the effectiveness of cannabinoids; although it does not pay great 
value to the ‘patient voice’ (Austin & Sutton, 2014). To explore the gap further, a systematic 
literature search was conducted, by the first author. In this review, it became clear that 
internationally, qualitative research, such as that investigating the experiences of persons with 
MS who use cannabis as a means of coping and leading an active life was minimal (Bottorff 
et al, 2013; Page & Verhoef, 2006; Banwell et al, 2016); and completely absent from UK 
nursing literature. We focus on the findings from the systematic review for the rest of this 
article.  
 
Literature Review: 
A literature search was conducted in 2018 to identify what is currently known about the 
experiences of people who use cannabis to manage symptoms associated with MS. 
The databases Medline, PsycInfo and CINHAL were used. Nine publications from four 
countries were included in the final review and included cross sectional surveys and qualitative 
interview methods. (See appendix 1). Search terms used were cannabis OR medical 
marijuana AND experience OR perspective. The PRISMA model was used to record the key 
aspects of the search and retrieval.  (See the adapted PRISMA table in diagram 1). 
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Diagram 1. PRISMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The significant finding was the absence of UK based qualitative research that discussed 
experiences of people who use cannabis for symptom control. Due to a growing momentum 
for drug policy reform cannabis for medical purposes has recently been permitted by UK 
government (GOV UK, 2018) for use within certain conditions. This may influence further 
CINAHL 
2003-2018 
No. of Hits= 199 
 
 
MEDLINE 
2003-2018 
No. of Hits= 403 
PSYCINFO 
2003-2018 
No. of Hits= 123 
Limiters applied:  
English language and academic 
journal only 
CINAHL 
No. of Hits= 140 
MEDLINE 
No. of Hits= 309 
PSYCINFO 
No. of Hits= 92 
Inclusion/exclusion criteria applied: 
Participants over 18, International research papers, 
publications from 2003 onwards, papers discussing other 
forms of alternative therapy (not cannabis) were excluded. 
 
CINAHL 
Articles selected for 
review: 3 
MEDLINE 
Articles selected for 
review: 5 
PSYCINFO 
Articles selected for 
review: 1 
532 papers excluded 
Duplications, not relevant to the 
topic of interest, published 
before 2003, not peer reviewed. 
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research in the topic. However, people cannot yet easily gain access to cannabis based 
medications through GPs and other healthcare professionals and may turn to, or, continue to 
access cannabis through other sources; making research more challenging. UK Government 
has stated that further research will be undertaken to distinguish what constitutes a medical 
product, dosing and long term-effects (GOV UK, 2019). From reading through the selected 
literature in this review, three themes were identified: i) perception of efficacy of cannabis 
among people with MS, ii) experience of associated stigma and iii) legal concerns among 
people with MS. These will now be discussed.  
 
Perception of efficacy of cannabis among people with MS  
A range of empirical research (Zajicek et al, 2012; American Academy of Neurology, 2014), 
anecdotal reports (Hornby & Sharma 2010) and case studies (MultipleSclerorsis.net 2018) 
regarding the use of cannabis among people with MS, have indicated that many people find 
this drug effective in the alleviation of symptoms such as sleep and mood disturbances and 
continence deterioration. The Cannabinoids in Multiple Sclerosis study (CAMS) (Zajicek et al, 
2003) was the first UK randomised placebo-controlled trial which aimed to evaluate the 
effectiveness of cannabinoids for treatment of spasticity and other symptoms related to MS. 
Of 630 participants recruited, 611 followed up to the primary end-point did not have any 
treatment effects on the primary outcome (change in overall spasticity score on the Ashworth 
sale). Although this study did not gain statistically significant results, subjective improvements 
were reported amongst 61% (n=121) of the cannabis extract group, 60% (n=108) in the group 
receiving THC and 46% (n=91) in the placebo group. Reasons for this improvement are 
unclear and it is interesting that almost half of those in the placebo group perceived a benefit, 
perhaps illustrating the advantages of participating in a research study (the placebo effect) 
(Rajagopal, 2006). However, the CAMS findings correspond with results from other studies 
examining the usefulness of cannabis as a medication. Trout & DiDonato (2015) created an 
online survey and used purposive sampling at government registered cannabis dispensaries 
within Arizona, US. The aims of this study were to describe participant characteristics, 
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perceptions and impressions of medical cannabis use and legalisation. Although the sample 
was made up of a population with diverse medical conditions, five people with reported MS 
were included and 130 people with reported muscle spasms. It was found 100% of participants 
with MS reported general relief associated with using cannabis and 75% stated they gained 
relief compared with other medications. In addition, 85.4% of all participants (n=367) reported 
they felt ‘somewhat more confident or much more confident’ in knowing that they had 
purchased a safe and uncontaminated product. Indicating the importance of medication safety 
as a key concern.  
The CAM and Arizona studies both indicated a high percentage of people with MS who felt 
they benefitted from cannabis use, although overall validity in the latter can be questioned for 
a number of reasons. For example, inclusion and exclusion criteria were not discussed which 
means that anyone who used dispensaries within Arizona and had access to the internet could 
have been included in the study sample. This influences the reliability of the results in relation 
to persons with MS. However, another study (Kindred et al, 2017) also produced similar 
findings. A strength of Kindred et all’s (2017) large study is that it explicitly stated the websites 
to which the survey hyperlink was uploaded, thus ensuring the researchers knew where 
recruitment took place (MS Society and Michael J Fox Foundation websites) which increased 
rigour. The survey remained online for eight months and was viewed 801 times with 595 
participants included in the final data set. The majority of participants (76%) reported living 
with Parkinson Disease (PD) and 24% with MS. Arguably participants with PD were over-
represented within the study and findings may not reflect the experiences of persons with MS. 
Cannabis use was reported in 44% of participants, with 74% of this group declaring it was for 
medical purposes only. Current cannabis users gained lower scores within the Guys 
Neurological Status Scale, specifically in memory (p=0.30), mood (p=0.002) and fatigue 
sections (p=0.009). An interesting finding was people with MS found cannabis more effective 
in symptom management than respondents with PD (p=0.002).  
In summary, only one study demonstrated statistically significant findings about the influence 
of cannabis (Kindred et al, 2017), in relation to its effects on memory, mood and fatigue. 
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However, many participants perceive they are receiving benefits from the use of this drug, 
which is likely to influence their use of it. The research papers all declare a need for further 
research in the efficacy of cannabis as a medicine. While most research has been undertaken 
in the US and Canada where, in some areas, cannabis is now legalised for medical use, there 
is a need for more research within the UK to better understand how people living with MS 
experience the effects of  this drug, their patterns of use and the challenges they face.  
 
Experience of associated stigma  
As there is currently a blurring of what constitutes a medical cannabis product in the UK (MS 
Trust 2018) people using cannabis for the relief of symptoms associated with MS could be 
subject to potential stigma. Stigma and the associated judgement can have a powerful impact 
on the way people interact with others and therefore may influence whether cannabis use is 
disclosed to the community nurse (Satterlund et al, 2015). Illicit drug users, for example, report 
experiencing a level of discrimination due to the labelling of this being a lifestyle choice 
(Sleeper & Bochain 2013). As a result these individuals have been found to receive a poorer 
quality of healthcare (Luoma et al, 2014). Around the same time, Bottorff et al (2013) reported 
that persons using cannabis for medical purposes experienced stigma. They attributed this to 
three reasons: cannabis is considered a recreational drug, current criminal penalties are 
associated with its use and cannabis is associated with vulnerability (current illness and level 
of disability). With regard to social stigma one participant stated: 
 
 “Nobody turns around and says you’re a junkie if you have terminal cancer and are 
on heroin. But it doesn’t matter why you’re on marijuana, if you’re on marijuana “you’re 
a pothead and get the hell away from me.” (Bottorff et al, 2013, pg. 4)  
 
This highlights that people can face judgement from the use of this drug although potential 
benefits are present. Moreover, Bottorff et al (2013) identified that those who used cannabis 
would attempt to keep this private from others. One participant said: 
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“Keep your mouth shut, grow it, use it, don’t tell anybody, don’t even tell your family, 
don’t tell your friends, keep it to yourself and save your own life.”  (Bottorff et al, 2013, 
pg. 6) 
 
Research conducted by Page and Verhoef (2006) found that participants talked of ‘testing the 
waters’ to gauge how healthcare professionals would react. One participant highlighted: 
 
“It took me a while just because I wasn’t sure of what their reaction would be. So, you 
just sort of slide little things in here and there.” (Page and Verhoef, 2006, pg. 69) 
 
If a negative attitude was anticipated, information regarding use was not divulged. Bottorff et 
al (2013) provide rich and detailed accounts of conversation from the interviews and direct 
quotes were included in the paper, thus increasing the research trustworthiness and 
authenticity. Participants were recruited through four British Columbia community-based 
cannabis dispensaries and an online forum for medicinal cannabis. This study included 
participants living with other conditions such as cancer, which means that the findings may 
not necessarily reflect the experiences of persons with MS. Further, two participants with 
neurological disorders were included without the researchers explicitly stating what these 
were. Data were collected through semi-structured face-to-face or telephone interviews as the 
researcher wished to gain an in-depth account of personal experiences. This may have been 
beneficial as it may have afforded the participants anonymity to discuss cannabis use openly. 
However, telephone interviews can also result in the absence of visual cues, loss of non-verbal 
data and may compromise rapport between interviewer and interviewee, therefore affecting 
data interpretation and dependability of findings (Novick, 2008).  
Page & Verhoef (2006) interviewed people with MS in order to describe medical cannabis use 
from their perspective. Participants (six men and eight women) responded to a survey, which 
was mailed to a sample of 780 persons who attended an MS clinic in Calgary. The paper 
reports data saturation was reached, i.e. participants were interviewed until there was no new 
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information found, therefore increasing trustworthiness of the findings (Saunders et al, 2017). 
The perceived effects were associated with a sense of relaxation and relief of specific 
symptoms although some participants described negative side effects such as fatigue and 
balance problems. Participants reported keeping their use of cannabis private through fear of 
judgement from others and resonates with the conclusions of Bottorff et al (2013). The findings 
also correspond with those of Banwell et al (2016) who noted that 14.1% of participants stated 
their feeling toward a friend would change if they discovered they were using cannabis. 
Furthermore, 28.6% stated they would feel uncomfortable if people around them were using 
cannabis. These findings are particularly interesting as participants involved in this study all 
had a clinical diagnosis of MS and indicates that some people’s feelings would change towards 
a person using cannabis. While these studies were conducted in the US and Canada their 
findings are likely to be applicable to the UK context where cannabis for medical purposes has 
recently been permitted. In summary, it could be suggested that people living with MS who 
use cannabis can potentially experience judgement from others. Bottorff et al (2013) did 
represent strong findings in relation to this, however failed to state explicitly if people with MS 
were involved in the study, therefore may lack applicability to this population. Due to the recent 
change in law in the UK further research should be conducted in order to learn more about 
possible social stigma which has been shown to surround cannabis use and how people 
experience and cope with this. 
 
Legal concerns among people with MS 
The MS Society report (2017) highlighted that a large proportion of persons with MS use 
cannabis for symptom control, and many more are familiar with the potential benefits for their 
condition. However, due to a level of confusion regarding the recent change in legislation in 
the UK (Torjesen, 2018) alongside the illegality in other countries around the globe, some 
people choose not to use this drug through fear of prosecution or other legal or social 
sanctions. Chong et al (2006) explored the extent and patterns of cannabis use in South-East 
London using a cross sectional survey method and found that 71% of people with MS who 
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had never tried cannabis would be willing if it was available to them on prescription. These 
findings concur with those of Page et al (2003) who found that 96% of participants were aware 
of the potential benefits of using cannabis for their symptoms. Of participants who were aware 
of these benefits but had not tried the drug (n=222) the most significant reason given for not 
doing so was legal concerns (64%). The study also found 35% (n=67) of participants had tried 
cannabis at some point in their life in an attempt to manage symptoms and 8 people 
discontinued as a result of legal fears. A questionnaire was used to gather data, with the 
inclusion of a comments section enabling participants to elaborate further on their perceptions. 
This triangulation is advantageous to data collection in that it draws on more than one method 
in order to display a more accurate representation of findings (Carter et al, 2014). Both Chong 
et al (2006) and Page et al (2003) found many participants in their studies expressed 
eagerness for the legalisation of medicinal use in order for them to safely control symptoms 
and self-manage this condition.  
A retrospective study (Martinez-Rodriguez et al, 2008), conducted prior to legislation 
permitting the medically supervised use of cannabis in Spain, found that 52.6% of participants 
who did not currently use cannabis were aware it could help with the management of 
symptoms. In addition, 14.5% of this group stated it was because of the drugs illegality that 
the decision was made to avoid use. This reiterates that people are aware of the possible 
benefits but some are hindered from using due to fear of legal action. Furthermore, 83.4% of 
those who had never used cannabis stated they would support a future of legalisation. 
Martinez-Rodriguez (2008) also reinforced the potential dangers associated with using 
cannabis illegally. In the period when cannabis was illegal for medicinal use, participants 
reported that the most usual cannabis source was through people growing their own supply 
or obtaining from a friend or relative. It was found that when people were unable to grow their 
own controlled supply, for example due to a worsening in clinical symptoms or when they did 
not have someone to do this for them, there was the risk that that the individual would obtain 
and consume a non-reliable, un-controlled product. In summary, legal concerns are a strong 
deterrent for many people in different countries.  
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Discussion: 
This literature review has found that people who choose to use cannabis for MS as a form of 
‘self-help’, can face or fear social stigma (Bottorff et al, 2013; Page & Verhoef, 2006): similar 
to that described in the classic work of Goffman. Goffman (1963) contends that people can 
experience both internal and external stigma associated with a belief or behaviour, which lies 
outside the realms of normality, as defined by the majority. This causes an individual to be 
regarded as a rejected stereotype or undesired within the normal functioning of society 
(Goffman, 1963). A significant consequence for community nursing here is that people 
sometimes feel they cannot discuss or disclose cannabis use because of anticipated negative 
reactions and consequences on the relationship, although, cannabis has clear benefits for 
some (Zajicek et al, 2003; Trout & DiDonato 2015; Kindred et al 2017). This was also found 
to be the case in research carried out by the UK All Party Parliamentary Group (APPG) – but 
not retrieved in the search for this review. Findings showed 37% of people using cannabis for 
medical reasons did not discuss this with a healthcare professional, worryingly, 63% who had 
discussed cannabis use with their GP experienced a reciprocated negative attitude (28%), 
which, to some extent, is supported by the findings from this review.  
Person-centred care requires community nurses to work in partnership with people, engaging 
in healthful relationships providing encouragement for active involvement and decision-
making (QNIS, 2015). Therefore, community nurses require both sympathetic presence 
(McCormack & McCance 2017) and a professional understanding of the risks faced by 
persons with MS who use cannabis for symptom control, such as those stated in this review. 
In addition, they need to be aware that persons using cannabis illicitly may not immediately 
disclose that they are doing so when the nurse is undertaking assessments. The review has 
demonstrated that the community nurse could potentially face clinical dilemmas when working 
with people who use or are willing to use cannabis as a means of self-management (Farrell et 
al, 2014), therefore, problems may arise when aiming to offer person-centred care. The review 
has also shown that people strongly believe there are benefits cannabis may provide to help 
symptoms associated with MS. However, many remain fearful because of the drugs previous 
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legal status, and therefore, the ongoing debate of what is regarded as a medical product (GOV 
UK 2019). It is vital that community nurses hear these experiences in order to positively 
influence conversations when working with someone who uses cannabis for symptom relief in 
MS. This should promote a feeling of openness and honesty, allowing for meaningful 
conversation about cannabis use.  
Community nurses should also be aware of any safety concerns to which patients may be 
exposed. For example, obtaining illegal cannabis from someone potentially entering the home 
and selling this to the person. Where there may be serious risk or actual harm, the need for 
safeguarding clearly challenges the boundaries to risk taking and to confidentiality (NMC Code 
of Conduct, 2015). Where community nurses are aware of cannabis use alongside other 
medications, this should be, with consent, appropriately recorded in the care record alongside 
a risk assessment and any advice or health promotion; consistent with NMC standard 18.3 
(NMC Code of Conduct, 2015). 
The MS Society has been vocal about decriminalising cannabis for people with MS and the 
Royal College of Nursing (RCN) also began to back the future for legalisation (MS Society, 
2018; RCN 2018). This is highly relevant to community nursing due to recent drug policy 
reform and their close working relationship with persons living with MS.    
Community nursing teams need to have discussions about their values and beliefs on this 
issue and on their responses when encountering the issue in practice, keeping central that 
providing person-centred care is encompassed by working with the person’s values and 
beliefs and knowing what matters most to the person receiving care (McCormack and 
McCance, 2017). Drawing on research to provide evidence about the experiences of people 
with MS and their use of cannabis, can help community nurses to enter into more trusting and 
open relationships: an essential component of person-centred care. 
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Conclusion: 
The literature review has found there is a clear need for nurses to hear and understand 
people’s perceptions and experiences of using cannabis. Yet, it is apparent people may be 
un-willing to disclose cannabis use to friends, family and importantly, to community nurses 
due to social and potential legal repercussions and fear of disrupting relationships with 
community nurses.  Nurses aspire to provide holistic and compassionate care which is 
ethically and legally sound. Cannabis use among people with MS may present a challenge to 
the nurse’s way of working. Pre-understandings, values and beliefs should be brought to the 
forefront in order for nurses to critically reflect on and challenge non-person-centred care.  It 
is clear there is an untapped potential for further research, but also importantly, in working 
openly with the person and valuing what is important to them. 
 
 
  Key points:  
 People using cannabis for relief of symptoms of MS may fear stigma and judgement 
from others, including healthcare professionals, which may influence their willingness 
to disclose this to community nurses caring for them.  
 There is poor evidence about community nurses’ current perspectives and practices 
relating to cannabis use amongst persons with MS.  
 Community nurses need to be open to the possibility that persons living with MS may 
use cannabis illicitly and seek opportunities for open dialogue.   
 Further research examining the experiences of people who use cannabis for relief of 
MS and the approaches used by community nurses to support them is required to 
promote person-centred care.   
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Appendix 1. Table of Literature  
Author, year, 
country, setting 
Purpose  Sample size Type of 
research 
methods Inclusion/exclusion limitations Findings/results 
Banwell et al, 
2016, Canada. 
Participants 
recruited at a 
Neuropsychiatry 
clinic and a 
neurology clinic. 
To investigate 
patterns of 
use among 
people with 
MS and their 
attitudes 
towards 
cannabis. 
225, males and 
females.  
Quantitative  Questionnaire 
containing yes/no 
answers.  Broken into 
3 categories; 
demographic and 
neurological status, 
cannabis use and 
attitudes towards 
cannabis. Study was 
not explicit in 
describing data 
analysis. 
Inclusion- diagnosis 
of MS, Exclusion- 
intellectual 
disability. 
Self-reporting 
system which 
could be open to 
bias. This could 
have been likely 
among 
participants who 
were reporting 
symptoms 
associated with 
mental health. 
44 people (19.5%) 
currently use 
cannabis with 
smoking being the 
most favoured route. 
Men being more 
likely to use 
(p=0.007).Participants 
with higher level of 
education were more 
likely to believe 
cannabis could cause 
harm medically 
(p=0.006). Subjects 
who reported using 
anti-anxiety 
medication were 
more likely to 
disclose cannabis use 
(p=0.004). Attitudes 
towards use- 122 
participants approved 
of cannabis (54.3%) 
and 75 were neutral 
(33.2%). 98 
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participants (43.7%) 
in favour of 
legalisation for 
medical use. 198 
participants viewed 
the drug as helpful 
(87.6%) rather than 
harmful 108 (47.9%. 
32 participants 
(14.1%) stated their 
feeling toward a 
friend would change 
if they were using 
cannabis and 110 
(48.8%) stated they 
would be upset if a 
loved one was using 
cannabis. 64 
participants (28.6%) 
sated they would feel 
uncomfortable if 
someone was using it 
around them. 
Kindred et al, 
2017, USA. 
Participants were 
recruited online 
through an 
anonymous 
online hyperlink 
posted to 
recruitment 
To assess 
cannabis use 
in Parkinson’s 
disease (PD) 
and MS and 
compare 
results of self-
reported 
assessments 
of neurological 
595 included, 
males and 
females. 76% 
of people 
reported PD 
and 24% 
reported 
having MS. 
Quantitative  Online survey posted 
to the Michael J Fox 
Foundation and the 
national multiple 
sclerosis society 
webpages from 15 
Feb to 15 Oct 2016. 
survey collected 
demographics, 
cannabis use 
No inclusion or 
exclusion criteria. 
Anyone who had 
access to the 
internet could have 
participated. 
Self-reporting 
system which 
could be open to 
bias. Sample was 
limited to people 
who have access 
to the internet 
and one must be 
familiar with 
online tools. 
Cannabis use- 44% of 
participants reported 
to be current users 
and 74% of this 
sample stated their 
use was for medicinal 
purpose. Only 42% 
reported owning a 
medical cannabis 
card. MS participants 
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pages of 2 
websites. 
disability 
between 
current users 
and non-users 
(Non-users 
regarded as 
those who 
were not using 
cannabis at 
present and 
included 
people who 
have used it in 
the past). 
information, it used 
standardised 
questionnaires to 
assess neurological 
function, fatigue, 
balance and physical 
activity participation. 
(Guys neurological 
status scale (GNDS), 
Nottingham Health 
profile (NHP), fatigue 
severity scale (FSS), 
Activities of balance 
confidence (ABC), 
and the international 
physical activities 
questionnaire 
(IPAQ)). Data were 
analysed using chi 
square tests. 
Cannot verify 
legitimacy of 
user’s diagnosis.   
were more likely to 
have used cannabis in 
the past and also be 
current users 
respectively (p=0.001; 
p=0.001) also more 
likely to report the 
reduction of 
prescribed 
medication with 
cannabis use 
(p=0.001). Self-
reported scales- no 
correlation was found 
between disease 
diagnosis and 
cannabis use for any 
of the GNDS, NHP, 
FSS, ABC or IPAQ 
values (p=0.05), 
suggesting that 
differences between 
users and non-users 
were not due to 
disease diagnosis. 
Current cannabis 
users had lower sores 
on self-reporting 
scale GNDS (p=0.006) 
specifically within the 
memory (p=0.030) 
mood (p=0.002) and 
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fatigue (p=0.009) 
sections. 
Zajicek et al, 
2003. Undertaken 
on an out-patient 
basis at 33 
neurology and 
rehabilitation 
clinics across the 
UK 
The aim of the 
study was to 
test the notion 
that 
cannabinoids 
have a 
beneficial 
effect on 
spasticity and 
other 
symptoms 
associated 
with MS. 
630 
participants 
with stable 
MS, males and 
females. 
Quantitative  630 patients treated 
at 33 UK centres with 
oral cannabis extract 
(n=211), 
tetrahydrocannabinol 
(THC) (n=206) or a 
placebo (n=213). Trail 
duration was 15 
weeks and the 
primary outcome 
measure was a 
change in overall 
Ashworth score. 
Analysis was by 
intention to treat. 
Secondary measures 
were the Rivermead 
mobility index (RMI), 
a timed 10m walk, 
and 4 self-completion 
questionaries’-the 
United Kingdom 
neurological 
disability score 
(UKNDS), the Barthel 
index, the general 
health questionnaire 
(GHQ-30) and a 
series of 9 category 
rating scales.  
Inclusion-  Those 
with a clinically 
definitive diagnosis 
or laboratory-
supported MS who 
had had stable 
disease in the prior 
6 months and lead 
up to study, with 
an Ashworth score 
of > 2 in two or 
more lower limb 
muscle groups. 
Over 18 years of 
age Exclusion- any 
participant with 
ischaemic heart 
disease, those with 
active sources of 
infection and those 
currently taking 
medication which 
could affect 
spasticity, fixed 
tendon 
contractures, 
severe cognitive 
impairment, PMH 
of psychotic illness, 
major illness in any 
other body area, 
The risk of 
unmasking 
among groups 
and assessors. 
Capsules could 
not be made 
identical so each 
had a matched 
placebo. 38 
patients 
withdrew from 
study post 
randomisation 
due to multiple 
reasons listed 
within paper. 
611 patients were 
followed up to the 
end of the study (lost 
participants through 
discontinuation 
choice and deaths) 
The study discussed 
no treatment effects 
of the cannabinoids 
against the primary 
outcome (p=0.40) the 
estimated mean 
reduction in overall 
Ashworth score for 
participants taking 
cannabis extract 
compared with those 
in the placebo group 
was 0.32% and 0.94% 
in those taking THC 
compared with 
placebo. There was 
evidence in patient 
reported spasticity 
and pain (p=0.003) 
61% of cannabis 
extract group, 60% in 
the THC group and 
46% in placebo. 
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pregnancy and any 
anyone who has 
used THC at any 
time and the use of 
cannabis within the 
30 days leading up 
to commensal of 
study. 
Bottorff et al, 
2013. Canada. 
Patients recruited 
from 4 British 
Columbia 
community-based 
cannabis 
dispensaries and 
also through an 
online forum for 
medicinal 
cannabis users 
from 2007-2008.  
Aim of the 
study was to 
describe 
cannabis 
user’s 
perceptions of 
and responses 
to stigma 
attached to 
using medical 
marijuana. 
23 
participants, 
13 women and 
10 men. Two 
transgendered 
females were 
included in the 
women’s 
group (Male to 
female 
transgender). 
2 participants 
had 
neurological 
conditions (did 
not specifically 
state which) 
and 4 
participants 
reported 
having ‘other’. 
Qualitative  Utilising qualitative 
methodology, 
inductive analysis 
and purposive 
sampling in depth 
accounts could be 
drawn using semi 
structured 
interviews. These 
were face-to-face or 
over the phone 
interviews and 
participants were 
encouraged to speak 
about their beliefs 
and experiences of 
stigma. This was 
conducted at a time 
and place which was 
suitable for the 
participant. 
Interviews were 
conducted by trained 
research assistants 
and lasted around 1-
Inclusion-reported 
cannabis use in the 
last 30 days and for 
over 6 consecutive 
months, over the 
age of 19 to 
participate and 
English speaking.  
Exclusion- under 
the age of 19 and 
no reported 
cannabis use  
Experiences of 
and reactions to 
cannabis use 
could have 
differed if 
participants had 
been recruited 
from more 
conservative 
regions, this was 
due to the study 
being conducted 
in an area known 
for its illegal 
cannabis 
production and 
tolerance on 
recreational use. 
Most participants 
declared they 
were long term 
users making the 
choice to use 
cannabis for 
medical reasons 
Participants 
experience of stigma 
was related to 
negative views of 
cannabis as a 
recreational drug, 
using cannabis in the 
context of 
stigmatising 
vulnerability and 
criminal punishments 
associated with the 
drug. There were a 
number of strategies 
people used to try 
and manage stigma; 
conceal their 
medicinal cannabis 
use from others so 
they wouldn’t face 
external stigma, 
educating those who 
did not approve 
about the associated 
benefits it has for 
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3 hours. A short 
questionnaire was 
administered to 
those taking part 
requiring details of 
demographics, 
history of cannabis 
use and information 
regarding health 
issues which have 
influenced using 
medical cannabis.   
several years ago, 
therefore their 
experiences of 
stigma may differ 
from those who 
have just begun 
using. Due to 
purposive 
sampling it could 
be said that those 
who had 
experienced more 
negative stigma 
and who had 
made a decision 
to stop using for 
fear of its social 
and political 
ramifications are 
likely to be 
underrepresented 
in this study. 
them and their 
condition and lastly 
being responsible 
with their cannabis 
use. 
PAGE&VERHOEF, 
2006. Canada. 
Participants were 
recruited for the 
study through a 
mailed survey to 
780 patients from 
the MS clinic 
database in 
Calgary, Alta. 
Potential 
Aim of the 
study was to 
describe 
medical 
marijuana use 
from the 
perspectives 
of patients 
with multiple 
sclerosis. 
6 men and 8 
women with 
multiple 
sclerosis were 
recruited. 
qualitative Participants 
identified themselves 
to the researcher 
after receiving an 
invitation in the 
original mailed 
survey. Eligibility was 
confirmed and 
purposive sampling 
was used to recruit 
participants. Semi-
Inclusion- over 18 
years of age, and 
clinically definitive 
diagnosis of MS or 
laboratory 
supported. 
Exclusion-under 
the age of 18 
The study did not 
discuss any 
limitations and no 
limitations were 
documented. 
Descriptive accounts 
fell into 3 broad 
areas: patterns of 
use, legal and social 
concerns and 
perceived effects. 
Cannabis use 
patterns ranged from 
little use to very 
regular use and this 
was said to be 
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interviewees 
responded to the 
interview 
invitation within 
the survey. 
structured interviews 
were conducted by 
the first author. An 
interview guide was 
created which drew 
from the medical 
literature, media and 
written comments 
within the original 
survey. The interview 
guide was reflected 
these variables but 
was very flexible 
which allowed for 
participants to speak 
freely. Interviews 
were all tape 
recorded and 
transcribed with 
participants 
permission. 
Participants could 
withdraw from the 
study at any time and 
were also given the 
option to withdraw 
information from the 
tape recordings. 
influenced by supply, 
social factors and 
symptoms. Social 
concerns were 
centred around those 
who has disclosed 
their use of the drug. 
The perceived 
benefits were 
reductions in pain, 
spasms, spascitity, 
nausea, numbness, 
sleep problems, 
bladder and bowel 
problems, fatigue. 
Some reported it 
helped with being 
able to write, eat and 
drink and also with 
sexual functioning. 
There were a small 
number of side 
effects identified such 
as: a feeling of being 
‘high’, problems with 
cognition and 
balance. It was noted 
that although there 
are a small number of 
associated side 
effects the benefits 
the patients gained 
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made the risk 
acceptable. 
Maertinez-
Rogrigues et al, 
2008. Spain.  
participants 
recruited from 
two hospitals in 
Spain. 
The aim of the 
study was to 
evaluate the 
prevalence of 
cannabis use, 
related factors 
and degree of 
satisfaction in 
Spanish 
patients with a 
diagnosis of 
MS prior to 
the 
establishment 
of medically 
supervised 
use.  
175 
participants 
males and 
females  
Quantitative  Cross sectional 
questionnaire based 
surveys were handed 
out during routine 
medical visits to 
consecutive patients 
in two university 
based neurology 
clinics. The 
questionnaire 
contained 56 
detailed questions. 
Patients were 
assessed for their 
expanded disability 
status score (EDSS), 
progression index, 
multiple sclerosis 
severity score (MSSS) 
and the type of MS 
the patient was living 
with. Patients were 
classified as cannabis 
non-users, 
recreational users 
and medical users. 
The questionnaire 
was taken home with 
the patient to 
complete and then 
returned to the 
Inclusion- adult 
patient (did not 
specify exact age) 
and a diagnosis of 
MS based on 
McDonald Criteria. 
Exclusion- there 
were no exclusion 
criteria with the 
exception of 
moderate to severe 
cognitive 
impairment. 
The study did not 
discuss any 
limitations and no 
limitations were 
documented. 
Of the 175 patients 
who returned the 
survey, 145 Patients 
reported non-medical 
use (recreational) and 
30 reported 
medicinal use. At the 
time of the study 
cannabis was being 
used by 56.7% 
(17/30) of medicinal 
users. First cannabis 
consumption was 
after a diagnosis of 
MS in 15 (50%) of 
medical users. An 
improvement in 
symptoms was 
reported by 14 
(46.7%) medical 
users. Awareness of 
cannabis’ potential as 
a medicine, smoking 
use, pain, higher 
disability and lower 
age were all 
independently 
associated with 
medical use. It was 
also reported that 
most patients would 
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centre in a pre-paid 
envelope. Statistical 
analysis was 
undertaken once all 
data was collected.  
support legalisation 
for medicinal use and 
were willing to 
receive cannabis 
under medical control 
if legalised (83.4% of 
never-users and 
94.5% of users 
(p=<0.05). 
Troutt&DiDonato, 
2015. USA. 
Participants 
recruited from 
medical cannabis 
dispensaries 
located 
throughout 
Arizona   
Aim of the 
study was to 
discover 
patient 
characteristics, 
perceptions 
and 
impressions of 
medical 
cannabis 
legalisation. 
The study 
aimed to 
gauge how 
patients felt 
prior to 
medical 
legalisation 
and how they 
feel about it 
now. 
367 
participants. 
Males (63.8%) 
and ranged 
from 18-83 
years of age. 5 
participants 
had MS and 
130 
participants 
experienced 
muscle 
spasms. 
Quantitative  To protect 
confidentiality 
researchers 
approached 
dispensary owners 
for assistance in 
recruiting 
participants. Owners 
informed patients of 
the study and those 
interested were 
directed to a website 
which contained 
information on the 
study and patient’s 
rights if they chose to 
be involved. If the 
patient agreed to 
participate they 
checked a box and 
the survey questions 
appeared. Patients 
were asked about 
their condition, 
Inclusion- no 
inclusion criteria 
specified 
Exclusion- no 
exclusion criteria 
specified  
Due to 
recruitment 
taking place 
within cannabis 
dispensaries 
there could be an 
element of 
positive bias 
among those 
patients who use 
cannabis 
medically. Also, 
individuals who 
use cannabis as a 
means of 
medication and 
self-management 
but for whom 
cannabis is not 
effective were 
unlikely to 
participate.  
Perceived 
effectiveness of 
medical cannabis- in 
relation to 
participants with MS 
and muscle spasms it 
was found that 100% 
of participants with 
MS experienced 
general relief from 
using medical 
cannabis, 75% had 
relief compared to 
other medications 
and 33.30% of MS 
participants were 
using other 
medications less 
frequently. 76.20% 
Participants with 
muscle spasms noted 
general relief from 
cannabis use and 75% 
experienced relief 
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patterns and 
methods of cannabis 
use and perceptions 
of prior medical 
cannabis users. Each 
theme contained 
additional questions 
which were 
answered on a five-
point Likert type 
scale e.g. degree of 
relief experienced 
overall from 
consuming cannabis 
(1= no relief at all 
and 5=almost 
complete relief). Did 
not discuss method 
of data analysis. 
compared with other 
medications and 
91.40% of 
participants were 
using other 
medications less 
frequently. 89.1% of 
patients reported 
that acquiring 
cannabis after 
legalisation felt 
‘somewhat safer or 
much safer’ and 
85.4% reported that 
they had ‘somewhat 
more confidence or 
much more 
confidence’ in 
knowing they were 
purchasing a safe and 
uncontaminated 
product. 79.5% 
reported that the 
medical cannabis was 
‘somewhat more 
effective or much 
more effective’ in 
treating their 
conditions. Over 30% 
of patients used 
cannabis around once 
per day and the 
preferred method of 
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consumption was 
smoking with around 
40% of participants. 
Page et al, 2003. 
Canada. 
Participants were 
recruited from 
Calgary MS clinic 
database. 
The aim of the 
study was to 
describe 
cannabis use 
among this 
patient group 
including 
information 
on people’s 
beliefs, 
practices and 
experiences 
related to use. 
Survey was 
returned by 
420/673 
eligible 
participants. 
26% males and 
74% females. 
quantitative Survey was mailed to 
a possible total 
sample of 780. 107 
were undeliverable 
due to moving home 
or were deceased. 
673 eligible 
candidates and 
survey was returned 
by 420 in a pre-paid 
envelope. Questions 
within the survey 
were primarily close-
ended but there 
were some 
opportunities for 
participants to 
provide additional 
detail if answers 
were not applicable 
to them on that 
particular question. 
Participants were 
asked about 
sociodemographic 
information (age, sex 
marital status, level 
of education) and 
information on 
disease 
Inclusion-did not 
specify inclusion 
criteria 
Exclusion- patients 
for whom an 
address was not 
known and those 
who had not given 
blanket consent to 
be approached for 
research. Those 
under the age of 18 
were excluded as 
those with 
probable MS and 
not clinically 
definitive or 
laboratory 
supported. 
Data gained was 
subjective and 
must be 
interpreted 
cautiously. 
72% of respondents 
stated that it should 
be legally permissible 
for people to use 
cannabis for medical 
reasons, 23% had no 
opinion while 5% 
opposed. 96% stated 
they were aware of 
cannabis and its 
potential therapeutic 
benefits. Reasons 
given for not using 
cannabis by those 
who were aware of 
the potential benefits  
but who have not 
tried it (n=222) were: 
it’s an illegal 
substance (64%), 
concern surrounding 
side effects (34%), 
lack of knowledge on 
how to obtain it 
(34%) and the 
disbelief it would help 
alleviate symptoms. A 
total of 176 patients 
had reported trying 
cannabis with 67 for 
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characteristics 
(medication use, MS 
diagnosis and onset, 
pattern, disability 
and symptom 
experience. 
Questions on 
cannabis use 
included; reasons for 
use, patterns of use 
and perceptions of 
effects. Data were 
analysed in STATA 6 
computer 
programme to 
summarise 
responses. Content 
analysis was used to 
describe the textual 
comments. 
medical purposes. 43 
people had used it 
within the past 3 
months for symptom 
relief and 24 people 
had discontinued use. 
Reasons for 
discontinuation were 
cost (n=11) side 
effects (n=10) legal 
concerns (n=8) and 
lack of effectiveness 
(n=7). Multiple 
regression showed 
that education level, 
marital status and use 
of conventional 
medication were not 
factors which 
influenced cannabis 
use. However, sex, 
age, level of income 
and level of disability 
were all influencing 
factors for use. 
Comments were 
made from 35 
participants within 
the study ranging 
from cannabis effect 
and reasons for use/ 
non-use. 
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Chong et al, 2006. 
UK. Participants 
were recruited 
from neurology 
outpatient clinics 
at 2 hospitals in 
London and 1 in 
Kent. 
The aim of the 
study was to 
describe the 
extent and 
patterns of 
cannabis use 
among MS 
patients in 
South-East 
London and 
surroundings.  
Questionnaires 
completed by 
254/337 MS 
patients. 
Males and 
females.  
quantitative Patients with a 
diagnosis of MS who 
attended the 
neurology 
departments at 
either Kings College 
Hospital, Queen 
Elizabeth and the 
Medway hospital 
were given a self-
reported 
questionnaire. This 
was piloted in a local 
MS support group 
before 
administration to 
potential 
participants. The 
questionnaires 
included 
demographic details, 
MS history including 
disease duration and 
disability using the 
Guys Neurological 
Disability Scale. 
Patients were asked 
about current and 
previous use and 
other recreational 
drug use. A list of 
symptoms was 
included and patients 
Inclusion- did not 
specify inclusion 
criteria 
Exclusion- patients 
under the age of 
18, those with 
severe mental 
health problems 
and those who 
were unable or 
unwilling to give 
consent were all 
excluded from the 
study. 
Due to the self-
reporting nature 
of the 
questionnaire 
results may not 
be reliable and 
data yielded 
subjective results 
which must be 
applied 
cautiously. 
Total response rate of 
75%. 43% of patients 
reported using 
cannabis at some 
stage in their life 
(ever-users) of these 
68% (75/110) had 
used cannabis to help 
symptoms. 46 
participants (18%) 
had used cannabis in 
the last month 
(current users) of 
whom 12% used 
cannabis for 
symptom relief. 
Increasing disability, 
tobacco smoking, 
marital status were 
all independent 
factors which 
influence MS related 
cannabis use. 
Cannabis use was 
more common 
among patients who 
were chair-bound 
compared to those 
who could walk 
unaided. 71% of 
patients when asked 
said they would try 
the drug if it was 
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were asked about the 
perceived efficacy of 
cannabis in trying to 
manage these. Those 
would had used 
cannabis at least 
once were described 
as ‘ever-users’, those 
who were using 
cannabis at least 
once a month and at 
the time of the 
survey were 
described as ‘current 
users’. MS related 
cannabis use was 
described as 
individuals who 
reported that they 
had not used 
cannabis before they 
were diagnosed with 
MS and they had only 
stared using it 
because of MS or 
those who would not 
use cannabis if they 
did not have MS. 
Data were analysed 
using SPSS and 
STATA. Comparison 
was made between 
MS related use and 
available to them on 
prescription. 
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the rest of the group 
(non-users and 
recreational users). 
